Fannie Mae, Freddie Mac shares tumble after conservatorship comments
Todd Berard, the Chief Marketing Officer at BioLife Solutions Inc. (NASDAQ:BLFS), a $1.04 billion market cap company, recently sold 8,902 shares of the company’s common stock. The transaction, which took place on April 1, 2025, was executed at a price of $22.66 per share, amounting to a total value of approximately $201,719. The sale comes as InvestingPro data shows the stock has experienced a 9.1% decline over the past week, though it maintains a 37.3% gain over the past year.
Following this sale, Berard retains ownership of 135,956 shares in BioLife Solutions. The sale was conducted under a pre-established Rule 10b5-1 trading plan, designed to satisfy tax withholding obligations related to the vesting of restricted stock. According to InvestingPro analysis, the company maintains a "GOOD" overall financial health score, with analysts setting price targets between $30 and $34 per share. For deeper insights into insider trading patterns and comprehensive financial analysis, subscribers can access the full Pro Research Report, available exclusively on InvestingPro.
In other recent news, BioLife Solutions reported impressive financial results for the fourth quarter of 2024, with revenues reaching $22.7 million, surpassing analysts’ estimates of $21.3 million. The company posted a net loss of $2.0 million, which was smaller than the projected $4.4 million loss. For the entire year, BioLife Solutions achieved total revenue of $82.3 million, excluding $37.7 million from discontinued operations. The Cell Processing segment, a significant growth driver, saw a 31% year-over-year increase in revenue for the fourth quarter, marking the fifth consecutive quarter of growth. Analysts at H.C. Wainwright and Benchmark have raised their price targets for BioLife Solutions to $30, maintaining a "Buy" rating, reflecting confidence in the company’s performance and future prospects. KeyBanc Capital Markets also maintained an Overweight rating with a $33 target, highlighting the potential for revenue amplification through new product introductions. BioLife Solutions anticipates total revenue growth of 16-20% in 2025, with the Cell Processing segment projected to grow 18-21%. The company’s biopreservation media is currently incorporated into 17 approved cell and gene therapies, with expectations for further approvals and expansions in the coming year.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.